key: cord-0796513-pv7y6zks
authors: Fuady, Ahmad
title: Call for more investment in cost-effective tuberculosis care
date: 2021-05-13
journal: Lancet Reg Health West Pac
DOI: 10.1016/j.lanwpc.2021.100157
sha: a13d13148d366133eed4e3f8a78932cb37ccceb7
doc_id: 796513
cord_uid: pv7y6zks

nan

also a highly cost-effective strategy in a high TB prevalence setting [ 5 ] .

However, ACF has not been widely implemented in such setting because of limited health system capacity, inadequate resources, static model of TB care provision mainly restricted in healthcare facilities, and thus depending much more on passive case finding [ 6 , 7 ] . Another factor causing little progress in scaling up ACF to a broader local context is the lack of robust economic data and uncertain evidence of economic consequences for contacts, health systems, and national economic growth. The government then needs to be convinced that such a policy could benefit a more extensive economic context-not limited to what benefits disease epidemiology could be obtained or how cost-effective the strategy is. Janne Estill and colleagues then projected the cost-effectiveness and estimated the return on investments in TB care. They used the WHO-EPIC approach, which is based on a human capital augmented Solow model, and two alternatives regarding the relative impact of labor versus physical capital on the economic growth: if the economic growth is dominated by labor (labor-dominated) or contributed equally by physical capital and labor (equal contribution of labor and capital). Besides cost-effective or even costsaving, TB care would result in good returns on investmentranging from US$1 to US$49 per dollar spent using a labordominated approach and from US$2 to US$24 per dollar spent using the equal contribution of labor and capital approach.

Choosing the most suitable combination of programs is tricky. A combination of two effective strategies may not double the positive impact or produce uncertain effects. It is likely because of the bargaining effect between epidemiological impact and decreasing physical capital produced in the model. A moderate combination strategy, for example, moderate but targeted ACF, could produce a higher net benefit by increasing people's productivity. Thus, each country's National TB Program should translate it carefully in their context by addressing the TB burden, resources, physical capital es- timates, and practicality of each strategy adequately to obtain the most beneficial impact.

Although the estimation for region-level is still uncertain-and challenging, the findings provide insightful evidence to support much more investment in cost-effective TB care. With the COVID-19 pandemic, the global TB elimination effort s have been pushed back by 12 years [8] : a decreasing TB diagnosis and treatment by 23%, which is equal to 1 million missed cases; increasing TBrelated deaths by 20% [9] ; and increasing TB-affected families' likelihood of facing catastrophic costs [ 10 ] . These highlight that extraordinary effort s and investment in cost-effective TB care are inevitable and strongly encouraged.

Despite its negative impact, the COVID-19 pandemic also brings opportunities for service integration and scale-up cost-effective TB care. ACF, in some points, can be integrated with the COVID-19 contact tracing, a similar strategy that can be applied to GeneXpert for diagnosis. In the same vein, TB programs can learn from how the COVID-19 pandemic shapes the emergency infrastructure and response and become an integral part of the COVID-19 pandemic response system-instead of self-insulating from the main structure and keep running alone separately. To ensure the impactful investment, it needs specific, shaped country plans addressing its local context with improving healthcare workers' availability and capacity and-the most important-sustained funding and advocacy.

AF synthetize the literatures and wrote the commentary article himself.

I declare that I have no conflict of interest.

World Health Organization Global tuberculosis report 2020. Geneva: World Health Organization

Ending tuberculosis by 2030-Pipe dream or reality?

Tuberculosis in the Western Pacific region: estimating the burden of disease and return on investment 2020-2030 in four countries

World Health Organization Systematic Screening for Active Tuberculosis: Principles and Recommendations. World Health Organization

Household contact investigation for the detection of tuberculosis in Vietnam: economic evaluation of a cluster-randomised trial

Active case finding in tuberculosis-affected households: time to scale up

Passive case finding for tuberculosis is not enough

12 Months of COVID-19 Eliminated 12 Years of Progress in the Global Fight Against Tuberculosis

Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: a modelling study

COVID-19 and tuberculosis-related catastrophic costs